



**Restriction map and multiple cloning site (MCS) of pECFP.** Unique restriction sites are in bold. The *Xba I* sites in the 5' and 3' MCSs can be used to excise the ECFP gene.

### Description:

pECFP encodes an enhanced cyan fluorescent variant of the *Aequorea victoria* green fluorescent protein gene (GFP). The ECFP gene contains six amino acid substitutions. The Tyr-66 to Trp substitution gives ECFP fluorescence excitation (major peak at 433 nm and a minor peak at 453 nm) and emission (major peak at 475 nm and a minor peak at 501 nm) similar to other cyan emission variants (1–3). The other five substitutions (Phe-64 to Leu; Ser-65 to Thr; Asn-146 to Ile; Met-153 to Thr; and Val-163 to Ala) enhance the brightness and solubility of the protein, primarily due to improved protein folding properties and efficiency of chromophore formation (2, 4, 5).

In addition to the chromophore mutations, ECFP contains >190 silent mutations that create an open reading frame comprised almost entirely of preferred human codons (6). Furthermore, upstream sequences flanking ECFP have been converted to a Kozak consensus translation initiation site (7). These changes increase the translational efficiency of the ECFP mRNA and consequently the expression of ECFP in mammalian and plant cells.

The ECFP gene is flanked at the 5' and 3' ends by the two MCSs of the pUC19 derivative pPD16.43 (8). Thus, the ECFP coding sequence can be easily excised from the vector or amplified by PCR. In *E. coli*, ECFP is expressed from the *lac* promoter as a fusion with several additional amino acids, including the first five amino acids of the *LacZ* protein. Note, however, that if you excise the ECFP coding sequence using a restriction site in the 5' MCS, the resulting fragment will encode the native (i.e., nonfusion) ECFP protein. The pUC19 backbone of ECFP provides a high-copy-number origin of replication and an ampicillin resistance gene for propagation and selection, respectively in *E. coli*.

**Location of features:**

- *lac* promoter: 95–178
  - CAP binding site: 111–124
  - 35 region: 143–148; –10 region: 167–172
  - Transcription start point: 179
  - lac* operator: 179–199
- *lacZ*–ECFP fusion protein expressed in *E. coli*
  - Ribosome binding site: 206–209
  - Start codon (ATG): 217–219; stop codon: 1006–1008
- 5' multiple cloning site: 234–281
- Enhanced cyan fluorescent protein (ECFP) gene
  - Kozak consensus translation initiation site: 282–292
  - Start codon (ATG): 289–291; stop codon: 1006–1008
  - Insertion of Val at position 2: 292–294
  - ECFP mutations (Phe-64 to Leu, Ser-65 to Thr, and Tyr-66 to Trp): 481–489; Asn-146 to Ile: 727–729; Met-153 to Thr: 748–750; Val-163 to Ala: 778–780.
  - His-231 to Leu mutation (A→T): 983
- 3' multiple cloning site: 1010–1109
- Ampicillin resistance gene
  - Promoter: –35 region: 1485–1490; –10 region: 1508–1513
  - Transcription start point: 1520
  - Ribosome binding site: 1543–1547
  - β-lactamase coding sequences:
    - Start codon (ATG): 1555–1557; stop codon: 2413–2415
    - β-lactamase signal peptide: 1555–1623
    - β-lactamase mature protein: 1624–2412
- pUC plasmid replication origin: 2563–3206

**Primer Locations:**

- EGFP-N Sequencing Primer (#6479-1): 355–334
- EGFP-C Sequencing Primer (#6478-1): 942–963

**Propagation in *E. coli*:**

- Recommended host strain: JM109
- Selectable marker: plasmid confers resistance to ampicillin (100 µg/ml) to *E. coli* hosts
- *E. coli* replication origin: pUC
- Copy number: ~500
- Plasmid incompatibility group: pMB1/ColE1

**References:**

1. Heim, R., & Tsien, R. Y. (1996) *Curr. Biol.* **6**:178–182.
2. Mitra, R. D., et al. (1996) *Gene* **173**:13–17.
3. Heim, R. et al. (1994) *Proc. Natl. Acad. Sci. USA* **91**:12501–12504.
4. Cormack, B., et al. (1996) *Gene* **173**:33–38.
5. Yang, T. T., et al. (1996) *Nucleic Acids Res.* **24**:4592–4593.
6. Haas, J., et al. (1996) *Curr. Biol.* **6**:315–324.
7. Kozak, M. (1987) *Nucleic Acids Res.* **15**:8125–8148.
8. Fire, A., et al. (1990) *Gene* **93**:189–198.

**Note:** The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by BD Biosciences Clontech. This vector has not been completely sequenced.

**Notice to Purchaser**

Use of BD Biosciences Clontech's Living Colors™ products containing DNA sequences coding for mutant *Aequorea victoria* green fluorescent protein (GFP) variants or proteins thereof requires a license from Amersham Biosciences under U.S. Patent Nos. 5,625,048; 5,777,079; 6,054,321 and other pending U.S. and foreign patent applications. In addition, certain BD Biosciences Clontech products are made under U.S. Patent No. 5,804,387 licensed from Stanford University.

Not-For-Profit research institutes or entities are granted an automatic license with the purchase of this product for use in non-commercial internal research purposes, the terms of which are disclosed in detail in the license that accompanies the shipment of this product. Such license specifically excludes the right to sell or otherwise transfer this product or its components to third parties.

For-Profit research institutes or entities must obtain a license from Amersham Biosciences. E-mail: [gfp@amershambiosciences.com](mailto:gfp@amershambiosciences.com)

Please contact BD Biosciences Clontech directly for any other assistance, including purchasing and technical support. All companies and institutions purchasing Living Colors™ products will be included in a quarterly report to Aurora Biosciences, as required by the BD Biosciences Clontech/Aurora Biosciences license agreement.

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. BD Biosciences Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of BD Biosciences Clontech.

© 2002, Becton, Dickinson and Company